Oral formulations of biologically active material conjugates having linked biotin moieties, fatty acid moieties, or combinations thereof

JP2023551480A5Inactive Publication Date: 2024-11-28D&D PHARMATECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532339
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-27
Filing Date
2021-11-29
Publication Date
2024-11-28
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing oral formulations of therapeutic agents like proteins and peptides face low bioavailability due to degradation and low absorption rates in the gastrointestinal tract, leading to ineffective pharmaceutical efficacy.

Method used

Development of oral pharmaceutical formulations comprising bioactive agent conjugates attached to biotin and fatty acid moieties, combined with excipients such as bile acids, to enhance intestinal membrane permeation and protect against enzymatic degradation.

Benefits of technology

Substantially improves the absorption rate and stability of bioactive substances in the body, achieving enhanced oral bioavailability and pharmacokinetic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to an oral pharmaceutical composition comprising (i) a biologically active material conjugate, in which the biologically active material is conjugated with a biotin moiety, a fatty acid moiety, or a combination thereof, and (ii) an excipient, whereby the absorption rate of the biologically active material is significantly improved, thereby enabling oral administration of conventional drugs that are difficult to administer orally, such as proteins or peptides.The present invention relates to an oral formulation of a biologically active substance conjugate to which a biotin moiety, a fatty acid moiety, or a combination thereof is attached.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an oral preparation of a physiologically active substance conjugate to which a biotin moiety, a fatty acid moiety or a combination thereof is attached. More specifically, the present invention relates to an oral pharmaceutical preparation comprising (i) a physiologically active substance conjugate attached to a biotin moiety, a fatty acid moiety or a combination thereof, and (ii) an excipient.

Background Art

[0002] For a drug to act effectively, high bioavailability must be ensured. Bioavailability means the degree of drug utilized at the target site after drug administration, and this degree varies depending on the administration method, the target environment, etc. Depending on the mode of administration, the drug may be lost or decomposed during the process of delivery from the administration site to the target.

[0003] Typically, drug delivery of therapeutic agents including proteins and polypeptides is divided into parenteral administration and oral administration. Parenteral administration methods include intravenous injection, intramuscular injection, subcutaneous injection, sublingual administration, etc., while oral administration means taking the drug orally. Most therapeutic agents, such as proteins and polypeptides, are administered by parenteral methods in consideration of bioavailability, target environment, delivery process, etc., and parenteral administration methods are known to exert direct and rapid effects. However, parenteral administration may cause pain or discomfort to the patient, and side effects such as infections due to injection and air embolism may appear depending on the route. On the other hand, in the case of oral administration, it has the advantage in that it is simple and the effect can be continuously exerted by the method of direct administration from the mouth. Therefore, many pharmaceutical companies have tried to administer therapeutic agents by oral administration, but there is a problem in that drugs administered orally require resistance to acidic environment and enzymatic degradation, etc. because they pass through the digestive tract. In particular, proteins and peptides are known to have a low bioavailability of about 0.1% when administered orally.

[0004] To solve the problems of oral administration, attempts have been made to prepare separate [oral] formulations using surfactants and absorption enhancers together, or to enhance drug delivery by micronizing drug particles and adjusting the dosing frequency. Such oral insulin and oral GLP-1 analogs are being developed by major pharmaceutical companies, and in addition, various research and development activities for oral administration, such as interferon alpha, are in progress. However, peptide and protein drugs are substances that are difficult to administer orally, and various attempts have been made to solve this problem, but so far, it has not been clearly solved. In particular, peptide and protein drugs have the problem that the oral absorption rate is not high when administered orally, which results in the problem that the pharmaceutical effect is low if not properly formulated. Summary of the Invention Means for Solving the Problems

[0005] Field of the Invention An object of the present invention is to provide an oral pharmaceutical preparation by mixing a physiologically active substance conjugate having a biotin moiety, a fatty acid moiety or a combination thereof and having an excellent oral absorption rate with an excipient. More specifically, an object of the present invention is to efficiently improve the absorption rate of a physiologically active substance in the body by an oral formulation containing a physiologically active substance conjugate to which a biotin moiety and a fatty acid moiety are bound, and an excipient.

[0006] [Technical Solution] To achieve the above object, the present invention provides an oral pharmaceutical preparation comprising (i) a physiologically active substance conjugate bound to a biotin moiety, a fatty acid moiety or a combination thereof, and (ii) an excipient.

[0007] Another aspect of the present invention provides an oral pharmaceutical preparation comprising a physiologically active substance conjugate bound to a biotin moiety and a fatty acid moiety, and an excipient.

[0008] In one embodiment of the present invention, examples of excipients may include bile acids, their derivatives, or pharmaceutically acceptable salts thereof.

[0009] Furthermore, in one embodiment of the present invention, the bile acid is at least one selected from the group comprising glycocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, taurocholic acid, deoxycholic acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, and lithocholic acid.

[0010] Furthermore, one embodiment of the present invention may further include at least one selected from the group comprising alpha-tocopherol, malic acid, fumaric acid, ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, sodium phosphate, calcium phosphate, potassium phosphate, galactose, glucose, maltose, gallic acid, propyl gallate, and pharmaceutically acceptable salts thereof.

[0011] Effects of the invention The present invention provides the benefit of substantially improved absorption in the body by comprising a bioactive substance conjugate to a biotin moiety, a fatty acid moiety or a combination thereof, and an excipient. More specifically, the present invention provides the benefit of substantially improved absorption in the body by comprising an excipient that improves enzyme stability. [Brief explanation of the drawing]

[0012] [Figure 1] This figure shows the results of measuring the accumulation of hGH in Caco-2 cells, as well as the accumulation of oral formulations containing conjugates 68 and 69 according to embodiments of the present invention.

[0013] [Figure 2] This figure shows the results of measuring the blood glucose regulatory ability of insulin and oral formulations containing the conjugate 65 according to embodiments of the present invention.

[0014] [Figure 3]This figure shows the results of measuring the blood glucose regulatory ability of insulin and oral formulations containing conjugates 65 and 66 according to embodiments of the present invention.

[0015] [Figure 4] This figure shows the results of measuring the weight-reducing and food intake-reducing effects of oral formulations containing amirin and conjugates 33, 36, 39, 42, 61, 62, 63, or 64 according to embodiments of the present invention.

[0016] [Figure 5] This figure shows the results of measuring the blood glucose regulatory ability of an oral formulation containing the conjugate 52 according to an embodiment of the present invention. [Modes for carrying out the invention]

[0017] [Best mode for carrying out the invention] The present invention relates to (i) a bioactive substance conjugate comprising a biotin portion and a fatty acid portion, and (ii) an oral pharmaceutical formulation comprising bile acid, propyl gallate, or a combination thereof.

[0018] [Modes for carrying out the invention] Hereinafter, embodiments and examples of the present invention will be described in detail so that those skilled in the art to which the present invention belongs can easily implement the present invention.

[0019] However, the present invention can be embodied in many different forms and is not limited to the embodiments and examples described herein. Throughout the specification of the present invention, where a part "contains" a particular component, it means that other components may be further included, rather than excluding other components, unless otherwise specified.

[0020] Terms such as “approximately” and “substantially” are used throughout this specification to refer to values ​​that are equal to or close to the inherent values ​​of the stated manufacturing and material tolerances, insofar as they are used to aid in understanding the invention or to prevent unjust infringement by misuse of this disclosure. Terms such as “~(to) step” or “step of” used throughout this specification do not mean “step for ~”.

[0021] Throughout the specification of this invention, the term “the combination” as it appears in any expression in Markush form means at least one mixture or combination selected from the group containing the components described in the Markush form, and means that at least one selected from the group containing the components is included. Throughout the specification of this invention, the phrase “and / or B” means “and B, or A or B.”

[0022] The present invention relates to an oral pharmaceutical formulation comprising (i) a bioactive substance conjugate bonded to a biotin moiety, a fatty acid moiety, or a combination thereof, and (ii) an excipient.

[0023] In one aspect of the present invention, (i) is a bioactive substance conjugate in which a biotin portion and a fatty acid portion are linked.

[0024] In one embodiment of the present invention, the excipient is a bile acid, a derivative thereof, or a pharmaceutically acceptable salt thereof.

[0025] Furthermore, in one embodiment of the present invention, the bile acid is at least one selected from the group comprising glycocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, taurocholic acid, deoxycholic acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, and lithocholic acid.

[0026] Furthermore, one embodiment of the present invention may further include at least one selected from the group comprising alpha-tocopherol, malic acid, fumaric acid, ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, sodium phosphate, calcium phosphate, potassium phosphate, galactose, glucose, maltose, gallic acid, propyl gallate, and pharmaceutically acceptable salts thereof.

[0027] Typically, peptide and protein drugs are classified as Class 3 in the Biopharmaceutical Classification System (BCS) due to their high water solubility and limited absorption sites in the gastrointestinal tract. Peptide and protein drugs have high hydrophilicity and large molecular weights, making them susceptible to degradation by low-pH stomach acid and resulting in low intestinal absorption due to enzymatic attack by trypsin and other enzymes. Typically, the oral bioavailability (BA) of peptide and protein drugs is approximately 0.1%, making their use as pharmaceutical formulations difficult. To address this challenge, enteric-coated capsules are used to allow them to pass through the stomach; however, this method has limitations in that it cannot fundamentally improve the absorption rate of peptides and proteins.

[0028] In contrast, a bioactive substance conjugate, comprising a biotin moiety, a fatty acid moiety, or a combination thereof, according to one embodiment of the present invention, can promote absorption in the intestines by enhancing permeability to the intestinal membrane.

[0029] Furthermore, a bioactive substance conjugate, comprising a biotin moiety, a fatty acid moiety, or a combination thereof, according to one embodiment of the present invention, can exhibit outstanding pharmacokinetic effects.

[0030] Furthermore, a bioactive substance conjugate, comprising a biotin moiety, a fatty acid moiety, or a combination thereof, according to one embodiment of the present invention, can be protected from enzymatic degradation of bioactive substances, such as peptides, and ultimately can promote the permeation of bioactive substances through the intestinal membrane and their absorption in the intestines.

[0031] Furthermore, according to one embodiment of the present invention, a bioactive substance conjugate bound to a biotin portion, a fatty acid portion, or a combination thereof can be absorbed by active transport via sodium-dependent multivitamin transporters because it is bound to biotin, a type of water-soluble vitamin.

[0032] Furthermore, according to one embodiment of the present invention, the biotin portion, the fatty acid portion, or a combination thereof can bind to the active or inactive site of a physiologically active substance and therefore do not inhibit the activity of the physiologically active substance.

[0033] Furthermore, more specifically, the absorption rate of peptides or proteins can be further improved by preparing oral formulations by mixing bioactive substance conjugates, which are bound to the biotin portion, the fatty acid portion, or a combination thereof, with excipients.

[0034] In the present invention, "unsubstituted or substituted" means unsubstituted or substituted. "Substituted" means having one or more substituents, where substituents refer to chemical moieties that are covalently bonded or condensed to any atom of the main group, such as alkylene or heteroalkylene.

[0035] In this invention, "halo" refers to fluorine, chlorine, bromine, iodine, and the like.

[0036] In the present invention, "alkyl" refers to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of an aliphatic or alicyclic saturated or unsaturated hydrocarbon compound, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, n-propyl, n-butyl, n-pentyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, etc.

[0037] In the present invention, "heteroalkyl" is an alkyl group containing one or more heteroatoms, wherein the heteroatom is located at any one carbon atom of the alkyl group and replaces C, CH, CH2, or CH3.

[0038] In the present invention, "alkylene" refers to the divalent moiety obtained by removing a hydrogen atom from a carbon atom of an aliphatic or alicyclic saturated or unsaturated hydrocarbon compound.

[0039] In the present invention, "heteroalkylene" refers to alkylene containing one or more heteroatoms.

[0040] In this invention, "aryl" refers to a monovalent moiety obtained by removing a hydrogen atom from the aromatic ring atom of an aromatic compound having a ring atom. For example, "C 5-10 The term "aryl" refers to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound having 5 to 10 carbon ring atoms. Examples of aryl groups include those derived from benzene, acenaphthene, fluorene, phenalene, acephenanthrene, and aceanthrene.

[0041] In the present invention, "heteroaryl" refers to an aryl containing one or more heteroatoms, such as pyridine, pyrimidine, benzothiophene, furyl, dioxalanyl, pyrrolyl, oxazolyl, pyridyl, pyridadinyl, pyrimidinyl, isobenzofuran, indole, isoindole, indidine, indoline, isoindoline, purine, benzodioxane, quinoline, isoquinoline, quinoridine, benzoxazine, benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine, pteridine, perimidine, pyridoindole, oxantren, phenoxatin, phenazine, and phenoxazine.

[0042] In the present invention, "arylene" refers to the divalent portion obtained by removing a hydrogen atom from the aromatic ring atom of an aromatic compound having a ring atom.

[0043] In the present invention, "heteroarylene" refers to arylene containing one or more heteroatoms.

[0044] In the present invention, "alkenyl" refers to alkyl groups having one or more carbon-carbon double bonds, such as vinyl (-CH=CH2), 1-propenyl (-CH=CHCH3), isopropenyl, tenyl, pentenyl, and hexenyl.

[0045] In the present invention, "alkynyl" is an alkyl group having one or more carbon-carbon triple bonds, and examples of such alkyl groups include ethynyl and 2-propynyl.

[0046] In the present invention, when a portion of a general formula is defined as a specific compound, it includes forms obtained by combining that compound with other components.

[0047] According to one embodiment of the present invention, the biotin moiety can be represented by the following general formula A.

[0048] [ka] [In general formula A, X is a functional group that can bind to physiologically active substances. Y is a spacer, Z is a bonding unit, B is the following chemical formula A-1,

[0049] [ka] It can be expressed as, Z is the chemical formula A-1 [ka] It is connected to, T is a terminal group, m is an integer between 1 and 10. n is an integer from 0 to 10, and if n=0, Y is directly coupled to B or T. p is an integer, either 0 or 1.

[0050] According to one embodiment of the present invention, in general formula A, X is a functional group that can bind to a physiologically active substance. Functional groups, but not limited to them, are functional groups that can react with thiol groups, carboxyl groups and / or amine groups, such as maleimide, succinimide, N-hydroxysuccinimide, aldehydes, carboxyl groups, carboxyl esters, succinimidyl esters, tetrafluorophenyl, -O-tetrafluorophenyl (TFP, 2,3,5,6-tetrafluorophenyl), tetrafluorophenyl esters, pentafluorophenyl (PFP), pentafluorophenyl esters, -O-benzotriazole, benzotriazole, sulfotetrafluorophenyl (STP), sulfodichlorophenyl (SDP), nitrophenol and nitrophenyl carbonate (NPC).

[0051] In one embodiment of the present invention, when functional group X is bound to a physiologically active substance, it may retain its structure, or it may be removed or modified.

[0052] Y is a spacer and may have a structure that is cleavable within the body. However, it is not limited to this; for example, Y may be directly bonded, or it may contain substituted or unsubstituted alkylenes, -O-, -C(O)NR-, -C(O)O- or -C(O)-, -NR-, -NOR-, or similar. More specifically, Y may be directly bonded, or the structure of Y may contain substituted or unsubstituted C 1-50 Linear alkylenes, substituted or unsubstituted carbon atoms 1-50 Nonlinear alkylenes, substituted or unsubstituted carbon atoms 1-50 Linear heteroalkylenes, substituted or unsubstituted C 1-50 Nonlinear heteroalkylenes, substituted or unsubstituted C 1-50 Arylene, substituted or unsubstituted C 1-50 It may contain at least one of the group including heteroarylene, -O-, -C(O), -C(O)NR-, -C(O)O-, -S-, -NR-, or -NOR-, where R is hydrogen, or substituted or unsubstituted C 1-50 Alkyl, substituted, or unsubstituted C1-50 Aryl, or ethylene glycol repeating unit (-(CH2CH2O) n -. In the formula, n is an integer of at least 1 but not exceeding 20).

[0053] Z is a linking unit capable of binding to B and can include, for example, but not limited to, amino acids, polypeptides, alkylene, amines or polyamideamine structures.

[0054] Non-limiting examples of amino acids can include lysine, 5-hydroxylysine, 4-oxalysine, 4-thialysine, 4-selenalysine, 4-thiahomolysine, 5,5-dimethyllysine, 5,5-difluorolysine, trans-4-dihydrolisine (trans-4-dehydrolisine), 2,6-diamino-4-hexenoic acid, cis-4-dihydrolisine (cis-4-dehydrolisine), 6-N-methyllysine, diaminopimelic acid, ornithine, 3-methyornithine, α-methyornithine, citrulline, homocitrulline, arginine, aspartate, asparagine, glutamate, glutamine, histidine, ornithine, proline, serine, threonine, etc.

[0055] In the present invention, when n is 0, B or T can be directly bonded to X or Y (spacer).

[0056] In the present invention, T is a terminal group and can be hydrogen or NH2, but is not limited thereto.

[0057] In the present invention, when p is 0, B can be a terminal portion.

[0058] In the present invention, X-Y may together form a bioactive substance binding site.

[0059] According to an embodiment of the present invention, in general formula A, m can be an integer of 1 to 10, and more specifically, can be an integer, or 1 to 8, 1 to 5 or 1 to 4.

[0060] In one embodiment of the present invention, X is maleimide, succinimide, N-hydroxysuccinimide, succinimidyl succinate, succinimidyl glutarate, succinimidyl methyl ester, succinimidyl pentyl ester, succinimidyl carbonate, p-nitrophenyl carbonate, aldehyde, amine, thiol, oxyamine, iodoacetamide, aminooxyl, hydrazide, hydroxy, propionate, pyridyl, alkyl halide, vinyl sulfone, carboxyl, hydrazide, halogen acetamide, C 2-5 Alkinyl, C 6-20 Aryl disulfide, C 5-20 The group may be selected from heteroaryl disulfides, isocyanates, thioesters, iminoesters, and their derivatives.

[0061] In certain embodiments of the present invention, X is maleimide, N-hydroxysuccinimide, succinimidyl carbonate, p-nitrophenyl carbonate, thiol, aminooxyl, aldehyde, or amine.

[0062] In certain embodiments of the present invention, X is maleimide, N-hydroxysuccinimide, aldehyde, or amine.

[0063] In one embodiment of the present invention, Y is absent, or is substituted or unsubstituted linear or branched C 1-50 Alkylene, substituted or unsubstituted linear or branched C 1-50 Heteroalkylene, substituted or unsubstituted C 6-50 Arylene, or substituted or unsubstituted C 6-50 It is a heteroarylene, and if substituted, it includes at least one selected from the group including =O, -C(O)NH2, -OH, -COOH, -SH, =NH, and -NH2.

[0064] In one embodiment of the present invention, Y contains -C(O)-.

[0065] In one embodiment of the present invention, Y contains -C(O)NH-.

[0066] In one embodiment of the present invention, Y is a substituted linear or branched C 1-50 It is a heteroalkylene and contains at least one -C(O)-.

[0067] In one embodiment of the present invention, Y is -(C(O)) q -(CH2) r -(C(O)NH) s -(CH2) r -(OCH2CH2) t -(C(O)) q - and in the expression, q, r, s, and t are independently selected, q and s are 0 or 1, r is an integer from 1 to 20, and t is an integer from 0 to 20.

[0068] In one embodiment of the present invention, Y is -(CH2) r The equation is C(O)NHNH-, where r is an integer between 1 and 20.

[0069] In one embodiment of the present invention, Y is a repeating unit -C(O)-(OCH2CH2) u The expression includes -NH-, where u is an integer between 1 and 20.

[0070] In one embodiment of the present invention, Y is a repeating unit -C(O)-(OCH2CH2) u The expression includes -NH-, where u is an integer between 2 and 4.

[0071] In one embodiment of the present invention, Y contains an amino acid as a component.

[0072] In certain embodiments of the present invention, Y comprises glutamic acid, glutamine, glycine, isoleucine, or lysine as components, and each amino acid may exist in a conjugated form.

[0073] In certain embodiments of the present invention, Y comprises glutamic acid or lysine as an ingredient.

[0074] In embodiments of the present invention, Y contains a fatty acid as a component.

[0075] In a particular embodiment of the present invention, Y is C 12-24 It contains fatty acids, which may exist in a bonded form.

[0076] In one embodiment of the present invention, Y is a direct bond.

[0077] In one embodiment of the present invention, Z can be independently selected as follows: A) Forming an amino acid or its derivative together with X, or separately from X; B) Substituted or unsubstituted linear or branched C 1-50 It is a heteroalkylene, If substituted, it includes at least one selected from the group including =O, -C(O)NH2, -OH, -COOH, -SH, =NH, and -NH2. It is one of the following.

[0078] In one embodiment of the present invention, Z is connected to B by -NH-.

[0079] In one embodiment of the present invention, Z is a hydrophilic amino acid or a derivative thereof.

[0080] In certain embodiments of the present invention, Z may be selected from the group comprising lysine, arginine, histidine, glutamine, asparagine, threonine, cysteine, serine and its derivatives.

[0081] In one embodiment of the present invention, Z includes at least one glycerol, at least one polyethylene glycol, or a combination thereof.

[0082] it is, [ka] Includes, [ka] represents a binding site, and at least one of these binding sites has at least one [ka] These are combined, and in the expression, u is an integer from 1 to 20.

[0083] In one embodiment of the present invention, Z is [ka] Includes, [ka] A -(CH2)3NH- group is further bonded to it.

[0084] In one embodiment of the present invention, T is an amine, C 1-8 Alkyl, C 1-8 The group may be selected from the group comprising alkenyl, halo, hydroxy, thiol, sulfonic acid, carboxyl, phenyl, benzyl, aldehyde, azide, cyanate, isocyanate, thiocyanate, isothiocyanate, nitrile, and phosphonic acid.

[0085] In one particular aspect of the present invention, T is an amine.

[0086] In one embodiment of the present invention, the biotin portion is [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] It is selected from the group that includes it.

[0087] According to one embodiment of the present invention, the fatty acid portion is given by the following general formula B: [General formula B] X'-Y'-W [In the above formula, X' is a functional group that can bind to physiologically active substances. Y' is a spacer, W is a fatty acid. It can be represented as follows.

[0088] In this specification, fatty acids include carboxylic acids having long saturated or unsaturated aliphatic chains, which include, for example, but are not limited to, caprylic acid, lauric acid, palmitic acid, stearic acid, arachidic acid, cerotic acid (all types of saturated fatty acids), and myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, and alpha-linolenic acid (all types of unsaturated fatty acids).

[0089] According to one embodiment of the present invention, in general formula B, X' is a functional group that can be bound to a physiologically active substance. Here, X' is the same as X in general formula A. Therefore, in one embodiment of the present invention, when the functional group X' is bound to a physiologically active substance, it may retain its structure, or it may be removed or modified.

[0090] According to one embodiment of the present invention, in general formula B, W may correspond to a fatty acid. Here, fatty acids include all types of fatty acids, including simple, modified, added, and deleted ones.

[0091] In one aspect of the present invention, Y' is the same as Y in the above general formula A. Therefore, in one embodiment of the present invention, the spacer Y' may be directly bonded, or substituted or unsubstituted C in the structure of Y. 1-50 Linear alkylenes, substituted or unsubstituted carbon atoms 1-50 Nonlinear alkylenes, substituted or unsubstituted carbon atoms 1-50 Linear heteroalkylenes, substituted or unsubstituted C 1-50 Nonlinear heteroalkylenes, substituted or unsubstituted C 1-50 Arylene, substituted or unsubstituted C 1-50 It may contain at least one from the group including heteroarylene, -O-, -C(O), -C(O)NR-, -C(O)O-, -S-, -NR-, or -NOR-, where R is hydrogen or unsubstituted C 1-50 Alkyl, substituted, or unsubstituted C 1-50 Aryl or ethylene glycol repeating unit (-(CH2CH2O) n -. In the formula, n is an integer that is at least 1 but not greater than 20.

[0092] In one embodiment of the present invention, W is a substituted or unsubstituted linear or branched C. 1-60 Alkylene, substituted or unsubstituted linear or branched C 1-60 Alkenylene, substituted or unsubstituted linear or branched C 1-60 Heteroalkylenes, or substituted or unsubstituted linear or branched C1-60 If it is a heteroalkenylene and is substituted, it may be substituted with at least one selected from the group including =O, -C(O)NH2, -OH, -COOH, -SH, =NH, -NH2, and halo.

[0093] In one aspect of the present invention, W is one or more substituted C 12-24 Alkylene, or one or more substituted C 36-48 It is a heteroalkylene and, if substituted, may contain =O or -COOH.

[0094] In one embodiment of the present invention, W is a C which is substituted with at least one C 12-24 An alkylene, or a C36-48 heteroalkylene with at least one substitution, which may contain =O or -COOH if substituted.

[0095] In one aspect of the present invention, one or more substituted W are substituted or unsubstituted C12-24 saturated fatty acids, and if substituted, they contain -COOH.

[0096] In one embodiment of the present invention, the fatty acid portion has the following general formula B1: [General formula B1] X'1-Y'-C(O)-F1 [In the above formula, X'1 is maleimide, N-hydroxysuccinimide, aldehyde, amine, tetrafluorophenyl ester, or nitrophenol. Y' is a spacer, F1 is C 6-28 [It is a substituted or unsubstituted linear or branched alkylene, or a substituted or unsubstituted linear or branched heteroalkylene.] It may have.

[0097] According to one embodiment of the present invention, in general formula B-1, X1 may be the same as X in general formula A. Therefore, in one embodiment of the present invention, when functional group X1 is bound to a physiologically active substance, it may retain its structure, or it may be removed or modified.

[0098] Furthermore, in general formula B1, Y' can be the same as Y in general formulas A and B.

[0099] In one embodiment of the present invention, Y' is a substituted or non-substituted C 6-50 The heteroalkylene is linear or branched, and if substituted, it includes at least one selected from the group consisting of =O, -C(O)NH2, -OH, -COOH, -SH, =NH, and -NH2.

[0100] In one embodiment of the present invention, Y' may include -(CH2CH2O)- as a repeating unit.

[0101] In one embodiment of the present invention, Y' is a repeating unit -C(O)-(OCH2CH2) u The expression includes -NH-, where u is an integer between 1 and 20.

[0102] In one particular embodiment of the present invention, Y' is -C(O)-(OCH2CH2) as a repeating unit. u The expression includes -NH-, where u is an integer between 2 and 4.

[0103] In one embodiment of the present invention, Y' includes an amino acid or a derivative thereof as a component.

[0104] In certain embodiments of the present invention, Y' comprises glutamic acid, glutamine, glycine, isoleucine, or lysine as components, and each amino acid may exist in a conjugated form.

[0105] In certain embodiments of the present invention, Y' comprises glutamic acid or lysine as an ingredient.

[0106] In one embodiment of the present invention, F1 is a substituted or non-substituted C 10-28 They may be linear or branched alkylenes.

[0107] In certain embodiments of the present invention, at least one substituted W is substituted or unsubstituted C. 12-24 It is a saturated fatty acid and, if substituted, contains a -COOH group.

[0108] In a particular embodiment of the present invention, F1 is -(CH2) v The expression is -COOH, where v is an integer between 10 and 20.

[0109] In a particular aspect of the present invention, F1 is -C(O)-(CH2) v The expression is -COOH, where v is an integer between 10 and 20.

[0110] In a particular embodiment of the present invention, the fatty acid portion is [ka] [ka] [ka] [ka] [ka] It can be selected from a group that includes this group.

[0111] According to one embodiment of the present invention, the bond between the biotin moiety and the bioactive substance can be formed by various types of bonds. This can be formed by bonding the functional groups of the biotin moiety to the functional groups of the bioactive material, and can be formed, for example, as a thiol-ether bond or an amide bond, for example, but not limited to these.

[0112] In one example, the bond between the biotin moiety and the bioactive substance can be formed by the method shown in Reaction Equation 1 below. In Reaction Equation 1, [ka] This represents a physiologically active substance containing a thiol group, and represents the reaction between the biotin moiety containing maleimide according to the embodiment of the present invention and the thiol group (-SH) of a cysteine ​​residue present in the physiologically active substance. [ka]

[0113] In one particular example, the bond between the biotin moiety and the bioactive substance may be formed by the method shown in Reaction Equation 2 below. In Reaction Equation 2, [ka] This represents a physiologically active substance containing an amine group, and represents the reaction between the biotin moiety containing N-hydroxysuccinimide according to the embodiment of the present invention and the amine group (-NH2) present in the physiologically active substance. [ka]

[0114] According to one embodiment of the present invention, there are no particular limitations on the physiologically active substance.

[0115] In the present invention, a physiologically active substance refers to a substance that can be administered to the body for a specific purpose and that causes a physiological or biochemical reaction in the body.

[0116] According to embodiments of the present invention, the bioactive substance may be a substance used in a pharmaceutical formulation. For example, it may be a substance used for the prevention or treatment of diabetes, obesity, fatty liver disease, irritable bowel syndrome, neurodegenerative diseases, bone diseases, osteoporosis, human growth hormone deficiency, or cancer or non-alcoholic fatty liver disease. These are non-limiting examples, because the indications may vary depending on the type of bioactive substance.

[0117] According to one embodiment of the present invention, the bioactive substance may be a polypeptide or a non-peptidic polymer, but is not limited to these. Non-limiting examples include polypeptides, proteins, polysaccharides, or derivatives thereof. Non-limiting examples of bioactive substances include glucagon (glucacon), GLP-1 (glucagon-like peptide-1), GLP-2 (glucagon-like peptide-2), GIP (glucose-dependent insulinotropic polypeptide), exendin-4, insulin, parathyroid hormone, interferon, erythropoietin, calcitonin, amylin, serotonin, rituximab, trastuzumab, uricase, tissue plasminogen activator, thymoglobin, vaccines, heparin or heparin analogs, antithrombin III, filgrastim, plumrintide acetate, exenatide, eptifbatide, antibenin, IgG, IgM, HGH, thyroxine, blood coagulation factors VII and VIII, glycolipids acting as therapeutic agents, and their derivatives.

[0118] According to one embodiment of the present invention, it may be attached to the biotin portion.

[0119] By binding the biotin portion to a physiologically active substance, it is possible to avoid inhibiting the biological activity of the physiologically active substance, thereby enabling it to possess the same or improved biological activity as the physiologically active substance.

[0120] The bioactive substance may, but is not limited to, contain exposed -SH groups so that the biotin moiety can bind to the -SH group. In addition, the bioactive substance may contain exposed -NH3+ Exposed -NH3 so that the biotin moiety can bind to the group or -NH2 group. + It may contain a group or an -NH2 group.

[0121] According to one embodiment of the present invention, the binding site of the biotin moiety to the bioactive substance can be adjusted to bind while avoiding the site that exhibits activity.

[0122] Furthermore, according to one embodiment of the present invention, the fatty acid portion may be directly bound to the physiologically active substance. Furthermore, a portion of the fatty acid portion may be shared with the biotin portion. For example, in one aspect of the following embodiment, the biotin portions B35 and B36 share a fatty acid component, which is a part of the fatty acid portion. However, this is just one example and is not limited thereto.

[0123] According to one embodiment of the present invention, the fatty acid portion may be directly bound to the bioactive substance, and the terminal portion of the fatty acid portion that is not bound to the bioactive substance may be bound to the biotin portion.

[0124] Furthermore, according to one embodiment of the present invention, the fatty acid portion may be bound to the physiologically active substance at a site other than the site to which the biotin portion is bound.

[0125] In addition, the fatty acid portion may be bound to the active or inactive site of the biotin portion, and may exhibit the same properties as described above.

[0126] According to one embodiment of the present invention, both a biotin portion and a fatty acid portion may be bound to the bioactive substance, and a bioactive substance conjugate in which both the biotin portion and the fatty acid portion are bound can exhibit superior oral absorption rate, pharmacokinetics, enzyme degradation inhibition, and intestinal membrane permeability compared to conjugates in which only the biotin portion or only the fatty acid portion is bound.

[0127] According to one embodiment of the present invention, the bioactive substance may be glucagon, calcitonin, GLP-1, GLP-2, GIP, exendin-4, parathyroid hormone, insulin, amylin, human growth hormone, or a derivative thereof.

[0128] According to embodiments of the present invention, the physiologically active substance may be a polypeptide or a derivative thereof having any one of the amino acid sequences of SEQ ID NOs: 1 to 7 below. Specifically, the physiologically active substances of SEQ ID NOs: 1 to 7 are a glucagon derivative (SEQ ID NO: 1), GLP-1 (SEQ ID NO: 2), GLP-2 (SEQ ID NO: 3), GIP (SEQ ID NO: 4), exendin-4 (SEQ ID NO: 5), parathyroid hormone (SEQ ID NO: 6), and glucagon (SEQ ID NO: 7), respectively. Sequence ID 1: H(Aib)QGTFTSDYSKYLDEQAAKEFVQWLMNT Sequence ID 2: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR Sequence ID 3: HADGSFSDEMNTILDNLAARDFINWLIQTKITD Sequence ID 4: YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ Sequence ID 5: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS Sequence ID 6:SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF Sequence ID 7:HSQGTFTSDYSKYLDSRRAQDFVQWLMNT

[0129] In addition, the bioactive substance may be a protein having the amino acid sequences of SEQ ID NOs. 15 and 16, or a protein having the amino acid sequences of SEQ ID NOs. 17 and 16, and such protein is linked by disulfide bonds between the 6th and 11th cysteines of SEQ ID NOs. 15 or 17, between the 7th cysteine ​​of SEQ ID NOs. 15 or 17 and the 7th cysteine ​​of SEQ ID NOs. 16, and between the 20th cysteine ​​of SEQ ID NOs. 15 or 17 and the 19th cysteine ​​of SEQ ID NOs. 16. Specifically, the protein having the amino acid sequences of SEQ ID NOs. 15 and 16, or the bioactive substance having the amino acid sequences of SEQ ID NOs. 17 and 16, represents insulin (SEQ ID NOs. 15 (insulin A chain derivative) and 16 (insulin B chain) / SEQ ID NOs. 17 (insulin A chain) and 16 (insulin B chain)). Sequence ID 15 GIVEQCCTSICSLEQLENYCN Sequence ID 16:FVNQHLCGSHLVEALYLVCGERGFFYTPKT Sequence ID 17: GIVEQCCTSICSLYQLENYCN

[0130] According to one embodiment of the present invention, cysteine ​​substitution or insertion may be performed on the polypeptide to adjust the site of binding with the biotin moiety.

[0131] In non-restrictive examples, at least one amino acid in a polypeptide selected from the group containing the amino acid sequences represented by SEQ ID NOs: 1-7 may be substituted or inserted with a cysteine ​​amino acid. In this case, the biotin moiety is bound to the -SH group of the cysteine ​​amino acid.

[0132] Furthermore, at least one amino acid of a polypeptide selected from the group containing the above amino acid sequence may be substituted or inserted with a lysine amino acid. In this case, the biotin moiety is bound to the -NH2 group of the lysine amino acid.

[0133] Furthermore, polypeptides into which a cysteine ​​amino acid is inserted may have one of the amino acid sequences of SEQ ID NOs. 8 to 14 below. More specifically, the physiologically active substances of SEQ ID NOs. 8 to 14 below refer to the physiologically active substances of SEQ ID NOs. 1 to 7 that have been substituted or inserted with a cysteine ​​amino acid (for example, in the physiologically active substance of SEQ ID NO. 8, at least one of the amino acids of the physiologically active substance of SEQ ID NO. 1 is substituted with cysteine). Sequence ID 8: H(Aib)QGTFTSDYSKYLDEQAAKEFVQWLMNTC Sequence ID 9: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRC Sequence ID 10: HADGSFSDEMNTILDNLAARDFINWLIQTKITDC Sequence ID 11: YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQC Sequence ID 12: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSC Sequence ID 13:SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFC Sequence ID 14: HSQGTFTSDYSKYLDSRRAQDFVQWLMNTC

[0134] According to one embodiment of the present invention, a portion of the polypeptide may be substituted to adjust the site of binding to the biotin moiety.

[0135] Furthermore, according to one embodiment of the present invention, the polypeptide may be substituted or inserted with the amino acid lysine to adjust the site of binding to the biotin moiety.

[0136] In a non-restrictive example, at least one amino acid in the amino acid sequence represented by SEQ ID NO: 5 may be substituted or inserted with the amino acid lysine.

[0137] In another non-restrictive example, at least one amino acid in the amino acid sequence represented by Sequence ID No. 5 may be substituted with 2-aminoisobutyric acid (Aib) and the amino acid lysine may be inserted. In this case, the biotin moiety is bound to the -NH2 group of the lysine amino acid.

[0138] Furthermore, polypeptides that are partially substituted, or substituted or inserted with lysine amino acids, may have one of the amino acid sequences listed in SEQ ID NOs. 18-21 below. Specifically, the bioactive substances listed in SEQ ID NOs. 18-21 below refer to exendin-4 derivatives in which some of the amino acids of the bioactive substance in SEQ ID NO. 5 have been substituted or inserted. Sequence ID 18: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK Sequence ID 19: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSKKK Sequence ID 20: H(Aib)EGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK Sequence ID 21: H(Aib)EGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSKKK

[0139] According to one embodiment of the present invention, cysteine ​​substitution or insertion may be performed on the polypeptide to adjust the site of binding with the biotin moiety.

[0140] In non-restrictive examples, at least one amino acid in a polypeptide selected from the amino acid sequences of SEQ ID NOs: 1-7 may be substituted or inserted with a cysteine ​​amino acid, where the biotin moiety is bonded to the -SH group of the cysteine ​​amino acid.

[0141] Furthermore, at least one amino acid of a polypeptide selected from the group containing the above amino acid sequence may be substituted or inserted with a lysine amino acid. In this case, the biotin moiety is bound to the -NH2 group of the lysine amino acid.

[0142] Furthermore, a polypeptide with an inserted cysteine ​​amino acid may have one of the amino acid sequences of SEQ ID NOs. 8 to 14 below. More specifically, the physiologically active substances of SEQ ID NOs. 8 to 14 below refer to the physiologically active substances of SEQ ID NOs. 1 to 7 that have been substituted or inserted with a cysteine ​​amino acid (for example, in the physiologically active substance of SEQ ID NO. 8, at least one of the amino acids of the physiologically active substance of SEQ ID NO. 1 is substituted with cysteine). Sequence ID 8: H(Aib)QGTFTSDYSKYLDEQAAKEFVQWLMNTC Sequence ID 9: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRC Sequence ID 10: HADGSFSDEMNTILDNLAARDFINWLIQTKITDC Sequence ID 11: YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQC Sequence ID 12: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSC Sequence ID 13:SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFC Sequence ID 14: HSQGTFTSDYSKYLDSRRAQDFVQWLMNTC

[0143] According to one embodiment of the present invention, a portion of the polypeptide may be substituted to adjust the site of binding to the biotin moiety.

[0144] Furthermore, according to one embodiment of the present invention, the polypeptide may be substituted or inserted with the amino acid lysine to adjust the site of binding to the biotin moiety.

[0145] In a non-restrictive example, at least one amino acid in the amino acid sequence represented by SEQ ID NO: 5 may be substituted or inserted with the amino acid lysine.

[0146] In another non-restrictive example, at least one amino acid in the amino acid sequence represented by Sequence ID No. 5 may be substituted with 2-aminoisobutyric acid (Aib) and a lysine amino acid may be inserted, where the biotin moiety is bonded to the -NH2 group of the lysine amino acid.

[0147] Furthermore, polypeptides that are partially substituted, or substituted or inserted with lysine amino acids, may have one of the amino acid sequences listed in SEQ ID NOs. 18-21 below. Specifically, the bioactive substances listed in SEQ ID NOs. 18-21 below refer to exendin-4 derivatives in which some of the amino acids of the bioactive substance in SEQ ID NO. 5 have been substituted or inserted. Sequence ID 18: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK Sequence ID 19: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSKKK Sequence ID 20: H(Aib)EGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK Sequence ID 21: H(Aib)EGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSKKK

[0148] According to one embodiment of the present invention, the bioactive substance may be a polypeptide or a derivative thereof having the amino acid sequence of SEQ ID NO: 22 below. The bioactive substance of SEQ ID NO: 22 below refers to amyrin. SEQ ID NO: 22: KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY.

[0149] According to one embodiment of the present invention, a portion of the amino acid sequence represented by SEQ ID NO: 22 may be substituted or inserted in order to adjust the site of binding with the biotin moiety.

[0150] In an unrestricted example, at least one of the amino acids having the amino acid sequence represented by SEQ ID NO: 22 may be substituted with the amino acids proline, aspartic acid, or arginine. In another unrestricted example, at least one of the amino acids having the amino acid sequence represented by SEQ ID NO: 22 may be substituted with the amino acid lysine.

[0151] Furthermore, a polypeptide in which some of the amino acids represented by SEQ ID NO: 22 are substituted or inserted may have one of the amino acid sequences shown in SEQ ID NOs: 23 to 31 below. Specifically, the physiologically active substances shown in SEQ ID NOs: 23 to 31 below represent amyrin derivatives in which some of the amino acids of the physiologically active substance of SEQ ID NO: 22 are substituted or inserted. Sequence ID 23: KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYK Sequence ID 24: KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY Sequence ID 25: KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTYK Sequence ID 26: KCNTATCATQRLADFLRHSSPNFGAIPSSTNVGSRTY Sequence ID 27: KCNTATCATQRLADFLRHSSPNFGAIPSSTNVGSRTYK Sequence ID 28: KCNTATCATQRLADFLRHSSNNFGAIPSSTNVGSRTY Sequence ID 29: KCNTATCATQRLADFLRHSSNNFGAIPSSTNVGSRTYK Sequence ID 30: RCNTATCATQRLADFLRHSSNNFGAIPSSTNVGSKTY Sequence ID 31:RCNTATCATQRLADFLRHSSNNFGAIPSSTNVGSKTYK

[0152] According to one embodiment of the present invention, the bioactive substance may be a polypeptide or a derivative thereof having the amino acid sequence of SEQ ID NO: 32 below. The bioactive substance of SEQ ID NO: 32 below represents an exendin-4 derivative. Sequence ID 32: H(Aib)QGTFTSDKSKYLDERAAQDFVQWLLDGGPSSGAPPPS

[0153] According to one embodiment of the present invention, a deletion, substitution, or insertion may be made in part of the amino acid sequence of SEQ ID NO: 32 in order to adjust the site of binding with the biotin moiety.

[0154] In an unrestricted example, at least one amino acid in the amino acid sequence represented by SEQ ID NO: 32 may be substituted with the amino acids methionine, lysine, isoleucine, tryptophan, or glycine. In another unrestricted example, at least one amino acid in the amino acid sequence represented by SEQ ID NO: 32 may be deleted.

[0155] Furthermore, a polypeptide in which a portion of the amino acids represented by SEQ ID NO: 32 is deleted, substituted, or inserted may have one of the following amino acid sequences from SEQ ID NOs: 32 to 37. Specifically, the following physiologically active substances, SEQ ID NOs: 33 to 37, which have a portion of the amino acids of the physiologically active substance of SEQ ID NO: 32 deleted, substituted, or inserted, represent exendin-4 derivatives. Sequence ID 33: H(Aib)QGTFTSDKSKYLDERAAQDFVQWLMDGGPSSGAPPPS Sequence ID 34: H(Aib)QGTFTSDKSKYLDKIAAQDFVQWLIDGGPSSGAPPPS Sequence ID 35: H(Aib)QGTFTSDKSWYLDKIAAQDFVQWLLGGGPSSGAPPPS Sequence ID 36: H(Aib)QGTFTSDKSWYLDERAAQDFVQWLMGGGPSSGAPPPS Sequence ID 37: H(Aib)QGTFTSDKSKWLDKIAAQDFVQWLIGGGPSSGAPPPS

[0156] According to one embodiment of the present invention, at least one of the amino acids in the amino acid sequence represented by Sequence ID No. 12 can be substituted with 2-aminoisobutyric acid (Aib).

[0157] According to one embodiment of the present invention, a polypeptide in which at least one amino acid in the amino acid sequence represented by SEQ ID NO: 12 is substituted with 2-aminoisobutyric acid (Aib) and at least one amino acid is substituted with Des-amino-His(h) may have the amino acid sequences of SEQ ID NOs: 38-39. More specifically, the physiologically active substance of SEQ ID NO: 38 or 39, in which the amino acids of the physiologically active substance of SEQ ID NO: 12 are substituted, represents an exendin-4 derivative. More specifically, the physiologically active substance having the amino acid sequence of SEQ ID NO: 39 is a physiologically active substance in which at least one amino acid is substituted with Des-amino-His(h). Sequence ID 38: H(Aib)HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSC Sequence ID 39: H(Aib)HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSC

[0158] According to one embodiment of the present invention, at least one of the amino acids in the amino acid sequence represented by Sequence ID No. 8 can be substituted with lysine (Lys) or arginine (Arg).

[0159] A polypeptide in which at least one amino acid in the amino acid sequence represented by SEQ ID NO: 8 is substituted with lysine or arginine may have the amino acid sequences of SEQ ID NOs: 40-41. Specifically, the physiologically active substances of SEQ ID NOs: 40 or 41, in which the amino acids of the physiologically active substance of SEQ ID NO: 8 are substituted, represent glucagon derivatives. Sequence ID 40: H(Aib)QGTFTSDYSKYLDEQAAKEFVQWLMNTK Sequence ID 41: H(Aib)QGTFTSDYSKYLDEKRAKEFVQWLMNTC

[0160] According to one embodiment of the present invention, the bioactive substance may be a polypeptide having the amino acid sequence of SEQ ID NO: 42 or a derivative thereof. More specifically, the bioactive substance of SEQ ID NO: 42 represents a human growth hormone derivative. Sequence ID 42: MFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKISFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF

[0161] According to one embodiment of the present invention, a bioactive material to which a biotin moiety, a fatty acid moiety, or a combination thereof is bound can be covalently bonded with at least one selected from the group including peptides and non-peptide polymers, fatty acids, cholesterol, antibodies, antibody fragments, albumin and its fragments, nucleotides, fibronectin, transferrin, FcRn-binding materials, sugars, elastin, heparin, and derivatives thereof, or can form inclusion bodies (microspheres) thereby.

[0162] Non-peptide polymers may be selected from the group including polyethylene glycol (PEG), polypropylene glycol, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol (PVA), polysaccharides, dextran, polyvinyl ethyl ether, PLA (polylactic acid, polylactic acid), PLGA (polylactic acid-glycolic acid), lipid polymers, chitin, hyaluronic acid, and combinations thereof.

[0163] In the present invention, "derivative" means that a part of the chemical structure has been modified by deletion, substitution, addition, or similar means.

[0164] In this invention, "pharmaceutically acceptable" means that the substances contained therein cause little to no irritation to living organisms and do not inhibit their biological activity and properties.

[0165] In the present invention, "pharmaceutically acceptable salt" refers to, and is not limited to, a salt having desired biological activity that does not inhibit biological activity and properties in humans or animals, and includes inorganic salts (hydrochloride salts, sulfuric acid, phosphoric acid, nitric acid), organic acids (acetic acid, oxalic acid, maleic acid, fumaric acid, succinic acid, benzoic acid, ascorbic acid, tannic acid, pamoic acid, alginic acid, triethylamine, cyclohexylamine, pyridine), alkali metal salts (sodium salts, potassium salts), alkaline earth metal salts (calcium salts), ammonium salts, and their addition salts.

[0166] In the present invention, bile acids are amphiphilic molecules that can promote drug permeation through biological membranes. Bile acids can be absorbed in a form bound to a bioactive substance that is attached to the biotin portion, fatty acid portion, or a combination thereof of the present invention, thereby minimizing the loss of the bioactive substance during oral administration and improving its absorption rate in the body.

[0167] Furthermore, considering factors such as cellular stability, cytotoxicity, and absorption rate in the body, bile acid derivatives in which a portion of the bile acid has been substituted, deleted, or added can be appropriately selected.

[0168] In one embodiment of the present invention, the excipient comprises a bile acid, a derivative thereof, or a pharmaceutically acceptable salt thereof.

[0169] In certain embodiments of the present invention, the bile acid is at least one selected from the group comprising glycocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, taurocholic acid, deoxycholic acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, and lithocholic acid.

[0170] In certain embodiments of the present invention, the bile acid is one selected from the group comprising chenodeoxycholic acid, deoxycholic acid, cholic acid, glycocholic acid, taurocholic acid, and ursodioxyoxycholic acid.

[0171] In one embodiment of the present invention, the excipient may further comprise at least one selected from the group comprising alpha-tocopherol, malic acid, fumaric acid, ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, sodium phosphate, calcium phosphate, potassium phosphate, galactose, glucose, maltose, gallic acid, propyl gallate, and pharmaceutically acceptable salts thereof.

[0172] In certain embodiments of the present invention, the excipient may further comprise gallic acid, propyl gallate, or a pharmaceutically acceptable salt thereof.

[0173] In one embodiment of the present invention, the excipient may comprise two or more bile acids or pharmaceutically acceptable salts thereof. In certain embodiments of the present invention, the excipient may be kenodoxycholic acid, deoxycholic acid, ursodioxycholic acid, or a pharmaceutically acceptable salt thereof.

[0174] In one embodiment of the present invention, the weight ratio of (i) the bioactive substance bound to the biotin moiety to (ii) the excipient is 1:0.01 to 1000. If the excipient contains two or more different excipients, the above weight of the excipient means the weight of all excipients included.

[0175] More specifically, the weight ratio can be 1:0.01-900, 1:0.015-850, 1:0.018-800, 1:0.02-750, 1:0.025-700, 1:0.028-650, 1:0.03-600, 1:0.035-550, 1:0.038-500, 1:0.04-500, 1:0.042-500, 1:0.045-500, 1:0.048-500, 1:0.05-500, 1:0.05-450, 1:0.05-400, 1:0.05-350, 1:0.05-300, or 1:0.05-250.

[0176] In a more specific embodiment of the present invention, the excipients include a bile acid or a pharmaceutically acceptable salt thereof, and propyl gallate or a pharmaceutically acceptable salt thereof.

[0177] More specifically, the weight ratio of bile acid or a pharmaceutically acceptable salt to propyl gallate or a pharmaceutically acceptable salt may be 1:0.01 to 8. More specifically, the weight ratio may be 1:0.015 to 7.5, 1:0.018 to 7.5, 1:0.02 to 7, 1:0.025 to 7, 1:0.028 to 6.5, 1:0.03 to 6.5, 1:0.035 to 6, 1:0.038 to 6, 1:0.04 to 5.5, 1:0.042 to 5.5, 1:0.045 to 5, 1:0.046 to 5, 1:0.047 to 5, 1:0.048 to 5, 1:0.049 to 5, or 1:0.05 to 5.

[0178] More specifically, the weight of bile acid or its pharmaceutically acceptable salt may range from 1 mg to 1,000 mg. More precisely, the weight may be at least 25 mg, at least 50 mg, at least 100 mg, at least 150 mg, at least 180 mg, at least 200 mg, at least 210 mg, at least 220 mg, at least 230 mg, at least 240 mg, or at least 250 mg. However, the weight of bile acid or its pharmaceutically acceptable salt may be appropriately adjusted depending on the patient's body weight, dosage, number of administrations, etc.

[0179] More specifically, the weight of propyl gallate or a pharmaceutically acceptable salt thereof may range from 1 mg to 1,000 mg. More precisely, the weight may be at least 25 mg, at least 50 mg, at least 100 mg, at least 150 mg, at least 200 mg, at least 250 mg, at least 300 mg, at least 310 mg, at least 320 mg, at least 330 mg, at least 340 mg, or at least 350 mg. However, the weight of propyl gallate or a pharmaceutically acceptable salt thereof may be appropriately adjusted depending on the patient's body weight, dosage, number of administrations, etc.

[0180] In one embodiment of the present invention, even if the oral pharmaceutical formulation does not contain excipients, the oral absorption rate of the oral pharmaceutical formulation may be improved by the binding of the biotin portion and / or fatty acid portion.

[0181] In certain embodiments of the present invention, an oral pharmaceutical formulation may have an oral absorption rate that is at least 1.5 times better than that of a formulation in which no excipients are used.

[0182] Furthermore, by using the above-mentioned bile acids, their derivatives, or pharmaceutically acceptable salts thereof as excipients in oral pharmaceutical formulations, the oral absorption rate can be improved by 1.5 times or more.

[0183] In a more specific embodiment of the present invention, the oral absorption rate can be improved by 1.5 times or more by using propyl gallate or a pharmaceutically acceptable salt thereof as an excipient in an oral pharmaceutical formulation. Hereinafter, when the [formulation] contains propyl gallate or a pharmaceutically acceptable salt thereof, the oral absorption rate may be improved by 1.7 times or more compared to when only the bioactive substance is present; when the [bioactive substance] is bound to the biotin moiety and / or fatty acid moiety, the oral absorption rate may be improved by 1.8 times or more compared to when the [bioactive substance] is bound to the biotin moiety and / or fatty acid moiety and contains bile acid as an excipient.

[0184] In this specification, excipients may further include conventional pharmaceutically acceptable excipients. The bioactive material bound to the biotin portion of the present invention may be formulated using excipients, non-limiting examples of which include stabilizers, surfactants, plasticizers, lubricants, solubilizers, buffers, sweeteners, bases, adsorbents, flavoring and deodorizing agents, binders, suspending agents, antioxidants, glossing agents, coating agents, flavoring and deodorizing agents, flavoring and deodorizing agents, wetting agents, wetting agents, defoaming agents, chewing agents, cooling agents, colorants, sugar coating agents, isotonic agents, pH adjusters, mitigating agents, emulsifiers, adhesives, adhesion enhancers, thickeners, thickeners, foaming agents, excipients, dispersants, sprays, disintegrants, fragrances, desiccants, preservatives, preservatives, softeners, solvents, solubilizers, dissolving agents, fluidizing agents, and the like.

[0185] In the present invention, the oral pharmaceutical formulation may further include starch, calcium carbonate, sucrose or lactose, gelatin, etc. for solid preparations, and suspensions, internal solutions, emulsions, syrups, etc. for liquid preparations, and may further include lubricants, wetting agents, sweeteners, fragrances, preservatives, etc. In addition, calcium or vitamin D3 may be further added to enhance the efficacy as a therapeutic agent for proliferative diseases or autoimmune diseases.

[0186] Another embodiment of the present invention is to provide uses for the oral pharmaceutical formulation described above. The uses of the pharmaceutical formulation may be determined depending on the type of physiologically active substance.

[0187] Here, the intended use of a pharmaceutical formulation can be determined according to the type of physiologically active substance.

[0188] According to one embodiment of the present invention, the formulation may be used for the prevention or treatment of diabetes, obesity, fatty liver disease, irritable bowel syndrome, neurodegenerative diseases, bone diseases, osteoporosis, human growth hormone deficiency, anti-cancer or non-alcoholic fatty liver disease.

[0189] According to one embodiment of the present invention, if the bioactive substance is GLP-1, GLP-2, GIP, insulin, amylin, or a derivative thereof, the conjugate may be used for the prevention or treatment of diabetes. Specifically, a conjugate containing the bioactive substance of SEQ ID NO: 12 may be used for the prevention or treatment of diabetes. However, this example is illustrative and the present invention is not limited thereto.

[0190] Furthermore, according to one embodiment of the present invention, if the bioactive substance is parathyroid hormone or a derivative thereof, the conjugate may be used for the prevention or treatment of bone disease. Specifically, a conjugate containing the bioactive substance of Sequence ID No. 6 may be used for the prevention or treatment of bone disease. However, this example is illustrative and the present invention is not limited thereto.

[0191] According to one embodiment of the present invention, when the bioactive substance is hGH or its derivative, the conjugate can be used for preventing or treating human growth hormone deficiency. Specifically, the conjugate containing the bioactive substance of SEQ ID NO: 42 can be used for preventing or treating human growth hormone deficiency and can be used for preventing or treating human growth hormone deficiency. However, this example is illustrative and the present invention is not limited thereto.

Example

[0192] Hereinafter, the present invention will be described in detail with reference to embodiments and experimental examples. However, the following embodiments and experimental examples are intended to illustrate the present invention and the present invention is not limited thereto.

[0193] [Embodiment]

[0194] <Preparation of Biotin Moiety> List of Abbreviations HBTU: 3-[Bis(dimethylamino)methylidene]-3H-benzotriazol-1-oxide hexafluorophosphate (:3-[Bis(dimethylamino)methylidene]-3H-benzotriazol-1-oxide hexafluorophosphate) DIEA: Ethyldiisopropylamine HATU: 1-[Bis(dimethylamino)methylene]-1H-imidazo[4, or 5-b]pyridinium-3-oxide hexafluorophosphate (1-[Bis(dimethylamino)methylene]-H-imidazo[4,5-b]pyridinium 3-oxide hexafluorophosphate) DIC: Diisopropylcarbodiimide HOBt:: 1-Hydroxybenzotriazole MBHA: 4-Methylbenzhydrylamine hydrochloride Fmoc: 9-Fluorenylmethoxycarbonyl DMF: Dimethylformamide SPPS: Solid-phase peptide synthesis HPLC: High-performance liquid chromatography LCMS: Liquid Chromatography Mass Spectrometry

[0195] General SPPS method In some cases, solid-phase synthesis of peptides can be improved by using dipeptides protected by dipeptide amide bonds having groups that can be cleaved under acidic conditions. For example, 2-Fmoc-oxy-4-methoxybenzyl or 2,4,6-trimethoxybenzyl. The Fmoc-protected amino acid derivatives used are recommended reference materials supplied by Anaspec, Bachem, Iris Biotech, or Novabiochem, e.g., Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc- These included His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, or Fmoc-Val-OH. The N-terminal amino acid was Boc-protected at the alpha-amino group. For example, Fmoc-8-amino-3,6-dioxaoctanoic acid, Fmoc-tranexamic acid, Fmoc-isopicotinic acid, Fmoc-Glu-OtBu, and Fmoc-Lys(Fmoc)-OH were used, supplied by Anaspec, Bachem, Iris Biotech, or Novabiochem.

[0196] Peptide synthesis using SPPS

[0197] Peptides can be synthesized in link amide MBHA resin using general Fmoc chemistry with HBTU / DIEA, HATU / DIEA, or DIC / HOBt as coupling reagents. The combinations of reactants and coupling reagents used in the synthesis include the following: [Table 1]

[0198] An exemplary protocol for a peptide synthesis process using SPPS includes: 1) Add DMF to a container containing link amide MBHA resin and allow to expand for 2 hours (sub:0.68 mmol / g, 1.0 mmol, 1.47 g, or 5 mmol, 7.35 g, sub:0.68 mmol / g). 2) Add 20% piperidine / DMF and mix for 30 minutes. 3) Remove the solvent from 1) and 2) and wash with DMF (5 times for 30 seconds each). 4) Add the reactant (one of reactant #1 to #5), mix for 30 seconds, then add the coupling reagent corresponding to the reactant (one of coupling reagents #1 to #5) and perform nitrogen bubbling for 1 hour. 5) Add 20% piperidine / DMF and mix for 30 minutes. In the exemplary protocols 1) to 5) above, repeated synthesis may be performed using combinations of reactants and coupling reactants #1 to #5 more than once. To remove Fmoc, treatment with a 20% piperidine / DMF solution for 30 minutes was used.

[0199] General Procedures for Peptide Purification and Analysis

[0200] The unpurified peptide was dissolved in a suitable mixture of water, TFA, and ACN, purified using preparative HPLC, dried, and quantified. The conditions for purification using preparative HPLC included those shown in Table 2 below. [Table 2]

[0201] After purification using preparative HPLC, the final product was characterized using analytical HPLC or LC-MS. The biotin moieties shown in Table 3 were obtained.

Table 3

Chem.

Chem.

Chem.

Chem.

[0202] Furthermore, the following biotin moieties were obtained by Protocols 1) to 5), purification, and analysis for peptide synthesis using SPPS. In Table 4 below, X, Y, Z, and B are those included in the definition of General Formula A of the present specification.

Table 4-1

Table 4-2

Chem.

Chem.

Chem.

Chem.

Table 5

[0203] <Bioactive substances (polypeptides)>

[0204] The bioactive substance (polypeptide) may be prepared using methods known in the art, or a commercially available substance may be used. In the present invention, the sequence of the bioactive substance bound to the biotin moiety, fatty acid moiety, or a combination thereof is shown in Table 6 below. [Table 6-1] [Table 6-2] [Table 6-3]

[0205] <Embodiment: Preparation of physiologically active substances compounded with biotin, fatty acid, or a combination thereof>

[0206] [Example of preparation]

[0207] Using a DMSO solution to which 0.3% trimethylamine (TEA, Sigma) was added as the reaction solvent, 1:X (1:0.5-30) molar ratio mixtures of polypeptides from Table 6 and biotin moieties from Tables 3-4 were reacted at room temperature for at least 30 minutes each. Subsequently, 1:Y (1:0.5-20) molar ratio mixtures of polypeptide-biotin moieties and fatty acid moieties from Table 5 were prepared and reacted at room temperature for at least 90 minutes each. The reaction was stopped by adding a 1% trifluoroacetic acid solution equal to the volume of each mixture.

[0208] [Isolation, purification, and confirmation]

[0209] The reaction products were isolated and purified using reverse-phase high-performance liquid chromatography. A SUPERSIL ODS-1 column (10 × 250 mm, 5 μm, LB Science, South Korea) was used as the column. The mobile phase conditions were linearly varied while maintaining a flow rate of 4.7 ml / min using 30–50% solvent B (acetonitrile with 0.1% TFA added) and solvent A (distilled water with 0.1% TFA added). Peaks detected between 10 and 20 minutes were collected while monitoring with a UV absorption spectrometer at 280 nm. Concentration and purification of the collected peaks were performed using an ultracentrifugation filter with an appropriate molecular weight cutoff after volatilizing the organic solvent and TFA under vacuum. The purity of the purified material was confirmed using HPLC analysis. The analysis was performed at a constant temperature near room temperature using a Gemini C18 column (4.6 × 250 mm, 5 μm; Phenomenex, CA, USA). The analysis was performed using a gradient elution method at a flow rate of 1 mL / min, with a mobile phase consisting of a trifluoroacetic acid solution:acetonitrile mixture (with a specified mixing ratio). UV absorbance at 280 nm was observed.

[0210] <Embodiment: Polypeptide compounded with a biotin moiety, a fatty acid moiety, or a combination thereof>.

[0211] The above-mentioned substances were used as the biotin portion, fatty acid portion, and polypeptide. Methods known in the art or the methods of the above embodiments were used to attach the polypeptide to the biotin portion, fatty acid portion, or a combination thereof.

[0212] The polypeptides bound to the biotin portion, fatty acid portion, or a combination thereof are shown in Table 7 below (where molecular weight represents either measured or theoretical molecular weight). [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 7-5] [Table 7-6]

[0213] <Embodiment: Formulation of a physiologically active substance combined with the biotin moiety>

[0214] <Formulation>

[0215] The compound, which is a polypeptide (bioactive substance) bound to a biotin portion, a fatty acid portion, or a combination thereof, prepared according to the above examples, was formulated by dissolving it in a Hanks equilibrium salt solution (HBSS) having a specific composition of excipients.

[0216] Formulation Embodiment 1. Preparation of a dosage form containing conjugate 3, one bile acid, and propyl gallate, and measurement of the Caco-2 cell membrane permeability of the bioactive substance in the dosage form.

[0217] Conjugate 3, a physiologically active substance (polypeptide) bound to the biotin portion, was formulated by dissolving it in Hanks equilibrium salt solution (HBSS) having the excipient composition shown in Table 8, and its Caco-2 cell membrane permeability was measured.

[0218] First, to form a Caco-2 cell monolayer, fill a 12-transwell plate with 1.5 × 10⁶ cells per well. 5 Cells were dispensed and cultured for 3-4 weeks under CO2 conditions at 37°C. During the first week, the culture medium was changed every two days, and thereafter, the culture medium was changed every three days. Cells from 3-4 weeks after seeding were used for the experiment. To confirm the formation of a cell monolayer, the TEER value and Lucifer Yellow value were measured, and a TEER value of 300 Ω·cm was used. 2 Only cell monolayers with a measured Lucifer Yellow permeability of 3% or less were used. The transwells used for the experiment were washed with transport medium (HBSS), then incubated at 37°C in a CO2 incubator for 1 hour. Subsequently, 200 μL of the prepared drug and excipient formulation was added to the apical end, while the lateral and basal ends were treated with 1 mL of drug-free transport medium. After this, they were incubated at 37°C in a CO2 incubator for 2 hours. After 2 hours, 1 mL samples were taken from each lateral and basal end, and the permeability coefficient (Papp value) was measured using enzyme-linked immunosorbent assay (ELISA). The permeability coefficient (Papp value) was calculated as follows, and the results of the analysis are shown in Table 8. [Papp(10 -6 , cm / s) = (dC r / d t )×V r (A×C0)] ( * dC r -Concentration of the transmitted sample, d t - Drug processing time, V r - (Amount on the lateral side, A-transwell area, C0-initial drug concentration) [Table 8]

[0219] Formulation Embodiment 2. Preparation of a formulation containing the conjugate (3, 17, 52, 70) and one bile acid, and measurement of the Caco-2 cell membrane permeability of the physiologically active substance in the formulation.

[0220] The bioactive substances, prepared according to the above examples and bound to a biotin portion, a fatty acid portion, or a combination thereof, were formulated by dissolving them in a Hanks equilibrium salt solution (HBSS) having the excipient composition shown in Table 9, and the Caco-2 cell membrane permeability was measured.

[0221] First, to form a Caco-2 cell monolayer, fill a 12-transwell plate with 1.5 × 10⁶ cells per well. 5 Cells were dispensed and cultured for 3-4 weeks under CO2 conditions at 37°C. During the first week, the culture medium was changed every two days, and thereafter, the culture medium was changed every three days. Cells from 3-4 weeks after seeding were used for the experiment. To confirm the formation of a cell monolayer, the TEER value and Lucifer Yellow value were measured, and a TEER value of 300 Ω·cm was used. 2 Only cell monolayers with a measured Lucifer Yellow permeability of 3% or less were used. The transwells used for the experiment were washed with transport medium (HBSS), then incubated at 37°C in a CO2 incubator for 1 hour. Subsequently, 200 μL of the prepared drug and excipient formulation was added to the apical end, while the lateral and basal ends were treated with 1 mL of drug-free transport medium. After this, they were incubated at 37°C in a CO2 incubator for 2 hours. After 2 hours, 1 mL samples were taken from each lateral and basal end, and the permeability coefficient (Papp value) was measured using enzyme-linked immunosorbent assay (ELISA). The permeability coefficient (Papp value) was calculated as follows, and the results of the analysis are shown in Table 9. [Papp(10 -6 , cm / s) = (dC r / d t )×V r (A×C0)] ( * dC r -Concentration of the transmitted sample, dt - Drug processing time, V r - (Amount on the lateral side, A-transwell area, C0-initial drug concentration) [Table 9]

[0222] Formulation Embodiment 3. Preparation of a formulation containing the conjugate (68, 69), one bile acid (sodium chenodeoxycholate), and propyl gallate, and measurement of the Caco-2 cell membrane permeability of the physiologically active substance in the formulation.

[0223] The bioactive substances, prepared according to the above examples and bound to a biotin portion, a fatty acid portion, or a combination thereof, were formulated by dissolving them in a Hanks equilibrium salt solution (HBSS) having the excipient composition shown in Table 11, and the Caco-2 cell membrane permeability was measured.

[0224] First, to form a Caco-2 cell monolayer, 7 × 10⁶ cells per well are placed in a 96-transwell plate. 4 Cells were dispensed and cultured in a CO2 incubator at a temperature of 37°C. After 24 hours, the culture fluid was removed from each well, washed with HBSS, and then 100 μL of the prepared drug and drug containing excipients were added and cultured in a CO2 incubator at 37°C. After 8 minutes, each well was washed with PBS and treated with 10% formalin in 100 μL, and then allowed to reach room temperature. After 10 minutes, each well was washed with PBS and treated with 0.1% TRITON® X-100 in 100 μL, and then allowed to reach room temperature. After 10 minutes, each well was washed with PBS and blocked with 1% BSA for 1 hour. After this, it was treated with HRP anti-growth hormone antibody (1:1000). After 1 hour, each well was washed with PBST and Ultra TMB substrate solution was added. After 10 minutes, each well was treated with 2N HCl stop solution, and the absorbance at 450 nM was measured to calculate the intracellular accumulation of each substance.

[0225] The results were compared with polypeptide SEQ ID NO: 42 set as 100%. The measurement results are shown in Table 10 and Figure 1. [Table 10]

[0226] Formulation Embodiment 4. Preparation of a formulation containing the conjugate (65, 66), one bile acid (sodium chenodeoxycholate), and propyl gallate, and measurement of the blood glucose regulating ability of the physiologically active substance in the formulation.

[0227] The bioactive substances, consisting of a biotin portion, a fatty acid portion, or a combination thereof, prepared according to the above examples, were formulated by dissolving them in a vehicle having the excipient composition shown in Tables 11 and 12 (10 mM PBS (pH 7.4) containing 0.02% polysorbate 80). These formulations were then orally administered to mice, and their blood glucose regulatory ability was subsequently measured by glucose tolerance tests.

[0228] The measurement results are shown in Figure 2. For control 1, a polypeptide in which proteins were linked by disulfide bonds between cysteine ​​6 and cysteine ​​11 of SEQ ID NO: 15, between cysteine ​​7 of SEQ ID NO: 15 and cysteine ​​7 of SEQ ID NO: 16, and between cysteine ​​20 of SEQ ID NO: 15 and cysteine ​​19 of SEQ ID NO: 16 was dissolved in a vehicle. Furthermore, for control 2, the same polypeptide was dissolved in a preparation containing sodium chenodeoxycholate and propyl gallate. For control 3, conjugate 65, a physiologically active substance bound to the biotin portion, was dissolved in a phosphate buffer that did not contain bile acid or propyl gallate. The hypoglycemic effects of controls 1, 2, and 3 from 0 to 120 minutes after the glucose tolerance test were compared. As shown in Figure 2, the results showed that conjugate 65 exhibited superior hypoglycemic effects in the preparation containing one bile acid and propyl gallate.

[0229] The measurement results are shown in Figure 3. As controls, polypeptides linked by disulfide bonds between cysteine ​​6 and cysteine ​​11 of SEQ ID NO: 15, between cysteine ​​7 of SEQ ID NO: 15 and cysteine ​​7 of SEQ ID NO: 16, and between cysteine ​​20 of SEQ ID NO: 15 and cysteine ​​19 of SEQ ID NO: 16 were used. In the measurement results, as shown in Figure 3, the blood glucose levels of the control group were lower than those of the untreated group. Furthermore, it was found that after administration of conjugates 65 and 66, blood glucose levels were significantly lower than those of the control group (especially 20-40 minutes later). [Table 11]

[0230] Formulation Embodiment 5. Preparation of a formulation containing conjugates (33, 36, 39, 42, 61-64), one bile acid (sodium chenodeoxycholate), and propyl gallate, and measurement of the weight-reducing and dietary intake-reducing effects of the physiologically active substances in the formulation.

[0231] The bioactive substances, prepared according to the above examples and bound to the biotin portion, fatty acid portion, or a combination thereof, were formulated by dissolving them in a vehicle having the excipient composition shown in Table 13 (10 mM PBS (pH 7.4) containing 0.02% polysorbate 80), and then orally administered to mice. Weight loss and reduction in food intake were measured over 24 hours. The measurement results are shown in Table 14 and Figure 4. [Table 12-1] [Table 12-2]

[0232] Formulation Embodiment 6. Preparation of a formulation containing conjugate 3, one bile acid, and propyl gallate, and measurement of intestinal absorption of the physiologically active substance in the formulation.

[0233] The bioactive substance bound to the biotin portion of conjugate 3 was formulated by dissolving it in a vehicle (physiological saline or physiological saline containing 0.5% CMC) having the excipient composition shown in Table 15, and then administered to the duodenum of experimental rats (SD rats). The pharmaceutical behavior was compared. The results are shown in Table 15 below. [Table 13-1] [Table 13-2]

[0234] Formulation Embodiment 7. Preparation of a formulation containing conjugates (14, 16, 17, 18, 19), one bile acid, and propyl gallate, and measurement of intestinal absorption of the physiologically active substance in the formulation.

[0235] The bioactive substances, prepared according to the above examples and bound to the biotin portion, fatty acid portion, or a combination thereof, were formulated by dissolving them in a vehicle (physiological saline containing 0.02% polysorbate 80) having the excipient composition shown in Table 16, and then administered to the duodenum of experimental rats (SD rats). The pharmaceutical behavior was compared. The results are shown in Table 16 below. [Table 14]

[0236] Formulation Embodiment 8. Preparation of a formulation containing conjugate 17, one bile acid (sodium chenodeoxycholate), and propyl gallate, and measurement of intestinal absorption of the physiologically active substance in the formulation.

[0237] The biotin portion, fatty acid portion, or combination thereof, prepared according to the above examples, was dissolved in a vehicle having the excipient composition shown in Table 17. The vehicle was formulated by appropriately mixing polysorbate 80, propylene glycol, CMC, physiological saline, or phosphate buffer. After administering the formulations to the duodenum of SD rats, their pharmacological behavior was compared. The results are shown in Table 17 below. [Table 15] A) Formulation Embodiment 9. Preparation of a formulation containing conjugate 67, one bile acid (sodium chenodeoxycholate), and propyl gallate, and measurement of intestinal absorption of physiologically active substances in the formulation. B) The bioactive substance conjugate 67, bound to the biotin portion, was formulated by dissolving it in a vehicle having the excipient composition shown in Table 18 (10 mM PBS (pH 7.4) containing 0.02% polysorbate 80), and then orally administered to the duodenum of experimental rats (SD rats). max The concentration of physiologically active substances was measured in [location], but the result was C max These results were compared with those obtained by administering SEQ ID NO: 6, a bioactive substance not bound to the biotin portion, using the same formulation. The results are shown in Table 18 below. [Table 16]

[0238] Formulation Embodiment 10. Preparation of a solid dosage form containing conjugate 52, one bile acid, and propyl gallate, and measurement of oral absorption rate.

[0239] Solid dosage forms with the excipient compositions shown in Table 19 were prepared using conjugate 52, a bioactive substance bound to the biotin portion. These were orally administered to beagle dogs, and their pharmaceutical behavior was compared.

[0240] Solid dosage forms were prepared by mixing the bioactive substance with bile acid, propyl gallate, and excipients typically used in the manufacture of solid dosage forms (such as mannitol, crospovidone, and stearate). These were then prepared into granules using a dry granulation method and then into tablets using a tablet press. These tablets were then coated with an enteric coating using a coating machine. The tablets were prepared as immediate-release and sustained-release tablets by adjusting the amounts of binder and disintegrant. Under dissolution conditions (pH 6.8, 50 rpm, 37°C), at least 80% of the bioactive substance in the immediate-release tablets was dissolved within 60 minutes, and under dissolution conditions (pH 6.8, 50 rpm, 37°C), at least 80% of the bioactive substance in the sustained-release tablets was dissolved within 360 minutes. [Table 17] A) (PG: Propyl gallate, sCDC: Sodium chenodeoxycholate, sDC: Sodium deoxycholate, sCA: Sodium cholate, sUDC: Sodium ursodeoxycholate, sGC: Sodium glycocholate, sTC: Sodium taurocholate) B) Formulation Embodiment 11. Preparation of a formulation containing conjugate 52, one bile acid (sodium chenodeoxycholate), and propyl gallate, and measurement of the blood glucose regulating ability of the physiologically active substance in the formulation. C) The bioactive substances, consisting of a biotin moiety, a fatty acid moiety, or a combination thereof, prepared according to the above examples, were formulated by dissolving them in a vehicle having the excipient composition shown in Table 20 (10 mM PBS (pH 7.4) containing 0.02% polysorbate 80), and then orally administered to mice. Their ability to regulate blood glucose was measured by glucose tolerance tests. D) The measurement results are shown in Figure 5. As a control, conjugate 52 dissolved in phosphate buffer without bile acid and propyl gallate at two different doses was used, and the hypoglycemic effect from 0 minutes to 120 minutes after the glucose tolerance test was compared. As a result, as shown in Figure 5, compared to the control, a dose-dependent hypoglycemic effect was observed after administration of conjugate 52 contained in a formulation with one bile acid and propyl gallate. [Table 18]

[0241] Formulation Embodiment 12. Evaluation of the antidiabetic effect of the physiologically active substance in a formulation containing conjugate 3, one bile acid (sodium chenodeoxycholate), and propyl gallate.

[0242] The bioactive substance bound to the biotin portion, prepared according to the above examples, was formulated by dissolving it in a vehicle having the excipient composition shown in Table 21. These formulations were orally administered to mice twice a day for 8 weeks, and changes in glycated hemoglobin were measured.

[0243] The measurement results are shown in Table 21. Conjugate 3 dissolved in two different formulations was used as the test substance, and a glycated hemoglobin test was performed after administration for 8 weeks. As shown in Table 21, the glycated hemoglobin-reducing effect of conjugate 3 in formulations containing one bile acid and propyl gallate was confirmed to be superior to that of formulations containing Labrasol and poloxamer 188. [Table 19]

[0244] Formulation Embodiment 13. Evaluation of the antidiabetic effect of the physiologically active substance in a formulation containing conjugate 3, one bile acid (sodium chenodeoxycholate), and propyl gallate.

[0245] Conjugate 3, a bioactive substance bound to the biotin portion, was prepared by dissolving it in a vehicle having the excipient composition shown in Table 22. These preparations were administered to the duodenum of experimental beagle dogs, and their pharmaceutical behavior was compared. The results are shown in Table 22. [Table 20]

[0246] Formulation Embodiment 14. Evaluation of the antidiabetic effect of the physiologically active substance in a formulation containing conjugate 56, one bile acid (sodium chenodeoxycholate), and propyl gallate.

[0247] The bioactive substance bound to the biotin portion, prepared according to the above examples, was formulated by dissolving it in a vehicle having the excipient composition shown in Table 23. These formulations were orally administered to mice once daily for three weeks, and changes in glycated hemoglobin were measured.

[0248] The measurement results are shown in Table 23. The results of the glycated hemoglobin test after 3 weeks of administration confirmed that oral administration of conjugate 56 in the formulation containing one bile acid and propyl gallate exerted a glycated hemoglobin-reducing effect. [Table 21]

[0249] <Embodiment: Pharmaceutical preparation containing a pharmaceutically active substance bound to the biotin portion and an excipient>

[0250] Measurement of the solubility of each formulation

[0251] The solubility of the bioactive substance bound to the biotin portion prepared according to the above examples was measured in the formulations. Conjugate 3 was dissolved at a concentration of 2.2 mg / mL in a vehicle (physiological saline) or the excipients shown in the table below. The solution was then filtered, and the concentration of conjugate 3 in the solution was measured using HPLC. As shown in Table 24 below, the solubility of conjugate 3 in physiological saline was 0.081 mg / mL, but it was observed that the solubility of conjugate 3 improved by 12 to 27 times in the following combinations of excipients. [Table 22] Those skilled in the art will recognize, or be able to find, many equivalents to the specific embodiments of the Invention described herein, by conventional experimentation alone. Such equivalents are intended to be included in the following claims. The above description of this application is illustrative, and those skilled in the art to which this application belongs will understand that it can be easily modified into other specific forms without altering the technical idea or essential features of this application. It should be understood that the embodiments described above are illustrative and non-limiting in all respects. For example, each component described as a single type may be provided separately, and similarly, components described as separate may be provided in combined form. Any variations or modifications derived from the spirit and scope of the claims described below, as well as their equivalents, may be considered to be within the scope of the Invention.

[0252] [Industrial applicability] The oral formulation of the present invention can efficiently enhance absorption in the body and, therefore, can be usefully used in the pharmaceutical field.

Claims

1. (i) a bioactive agent conjugate attached to a biotin moiety, a fatty acid moiety, or a combination thereof; and (ii) Excipients 1. An oral pharmaceutical formulation comprising:

2. In the (i) bioactive substance conjugate bound to a biotin moiety, a fatty acid moiety, or a combination thereof, The physiologically active substance is Glucagon (Glugacon), GLP-1 (Glucagon-like peptide-1), GLP-2 (Glucagon-like peptide-2), GIP (Glucose-dependent insulinotropic polypeptide), Exendin-4, Insulin, Parathyroid hormone, Interferon, Erythropoietin, Calcitonin, Amylin, Serotonin, Rituximab, Trastuzumab, Uricase, Tissue plasminogen activator, Thymoglobin, Vaccine, Heparin or Heparin analogues, Antithrombin III, Filgrastim, Pramlintide acetate, Exenatide, Eptifibatide, Antivenin, IgG, IgM, HGH, Thyroxine, Blood coagulation factors VII and VIII, Glycolipids acting as therapeutic agents, and derivatives thereof.

2. The oral pharmaceutical formulation of claim 1, selected from the group comprising:

3. In the (i) bioactive substance conjugate bound to a biotin moiety, a fatty acid moiety, or a combination thereof, The physiologically active substance is Polypeptides consisting of the amino acid sequences represented by SEQ ID NOs: 1 to 14 and 18 to 42, and derivatives thereof 2. The oral pharmaceutical formulation of claim 1, which is one selected from the group comprising:

4. In the (i) bioactive substance conjugate bound to a biotin moiety, a fatty acid moiety, or a combination thereof, The physiologically active substance is A polypeptide consisting of the amino acid sequences represented by SEQ ID NOs: 15 and 16 or a derivative thereof, or a polypeptide consisting of the amino acid sequences represented by SEQ ID NOs: 17 and 16 or a derivative thereof.

2. The oral pharmaceutical formulation of claim 1, wherein

5. In the (i) bioactive substance conjugate bound to a biotin moiety, a fatty acid moiety, or a combination thereof, The biotin moiety has the following general formula A: [C18] [In the above general formula A, X is a functional group capable of binding to a biologically active substance; Y is a spacer, Z is a bonding unit; B is represented by the following chemical formula A-1: [C19] It is expressed as Z is a compound of the formula A-1 [C20] It is linked to T is a terminal group; m is an integer from 1 to 10; n is 0 or an integer from 1 to 10, and when n=0, Y is directly bonded to B or T; p is an integer of 0 or 1. The oral pharmaceutical formulation according to claim 1,

6. X, Maleimide, succinimide, N-hydroxysuccinimide, succinimidyl succinate, succinimidyl glutarate, succinimidyl methyl ester, succinimidyl pentyl ester, succinimidyl carbonate, p-nitrophenyl carbonate, aldehyde, amine, thiol, oxyamine, iodoacetamide, aminooxyl, hydrazide, hydroxy, propionate, pyridyl, alkyl halide, vinyl sulfone, carboxyl, hydrazide, halogen acetamide, C 2-5 Alkynyl, C 6-20 Aryl disulfide, C 5-20 Heteroaryl disulfides, isocyanates, thioesters, iminoesters, and their derivatives 6. The oral pharmaceutical formulation of claim 5, selected from the group comprising:

7. Y, Does not exist or Substituted or unsubstituted linear or branched C 1-50 Alkylene, substituted or unsubstituted linear or branched C 1-50 Heteroalkylene, substituted or unsubstituted C 6-50 Arylene, or substituted or unsubstituted C 6-50 Heteroarylene, When substituted, ═O, —C(O)NH 2 , -OH, -COOH, -SH, =NH and -NH 2 At least one selected from the group including:

6. The oral pharmaceutical formulation of claim 5.

8. Y is a repeating unit of -C(O)-(OCH 2 CH 2 ) u 6. The oral pharmaceutical formulation of claim 5, which contains -NH-, and u is an integer from 1 to 20.

9. 6. The oral pharmaceutical formulation of claim 5, wherein Y comprises as a moiety glutamic acid, glutamine, glycine, isoleucine or lysine.

10. Z can be independently selected from the following: A) together with or separately from X, forms an amino acid or a derivative thereof; B) Substituted or unsubstituted linear or branched C 1-50 Heteroalkylene, When substituted, ═O, —C(O)NH 2 , -OH, -COOH, -SH, =NH and -NH 2 At least one selected from the group including:

6. The oral pharmaceutical formulation of claim 5, wherein the formulation is any one of the following:

11. T, Amine, C 1-8 Alkyl, C 1-8 Alkenyl, halo, hydroxy, thiol, sulfonic acid, carboxyl, phenyl, benzyl, aldehyde, azide, cyanate, isocyanate, thiocyanate, isothiocyanate, nitrile and phosphonic acid 6. The oral pharmaceutical formulation of claim 5, selected from the group comprising:

12. In the (i) bioactive substance conjugate bound to a biotin moiety, a fatty acid moiety, or a combination thereof, The biotin moiety is [Case 21-1] [Case 21-2] [Case 21-3] [Case 21-4] [Case 21-5] [Case 21-6] [Case 21-7] [Case 21-8] [Case 21-9] [C21-10] [C21-11] [C21-12] [C21-13] [C21-14] 2. The oral pharmaceutical formulation of claim 1, selected from the group comprising:

13. In the (i) bioactive substance conjugate bound to a biotin moiety, a fatty acid moiety, or a combination thereof, The fatty acid moiety has the following general formula B: [General formula B] X'-Y'-W [In the above formula, X' is a functional group capable of binding to the biologically active substance; Y' is a spacer, W is a fatty acid. The oral pharmaceutical formulation according to claim 1,

14. X' is Maleimide, succinimide, N-hydroxysuccinimide, succinimidyl succinate, succinimidyl glutarate, succinimidyl methyl ester, succinimidyl pentyl ester, succinimidyl carbonate, p-nitrophenyl carbonate, aldehyde, amine, thiol, oxyamine, iodoacetamide, aminooxyl, hydrazide, hydroxy, propionate, pyridyl, alkyl halide, vinyl sulfone, carboxyl, hydrazide, halogen acetamide, C 2-5 Alkynyl, C 6-20 Aryl disulfide, C 5-20 Heteroaryl disulfides, isocyanates, thioesters, iminoesters, tetrafluorophenyl esters, nitrophenyl carbonates, nitrophenyl, and their derivatives The biologically active substance conjugate of claim 13, selected from the group comprising:

15. Y' is a direct bond, or The structure of Y is Substituted or unsubstituted C 1-50 Linear alkylene, substituted or unsubstituted C 1-50 Non-linear alkylene, substituted or unsubstituted C 1-50 Linear heteroalkylene, substituted or unsubstituted C 1-50 Non-linear heteroalkylene, substituted or unsubstituted C 1-50 Arylene, substituted or unsubstituted C 1-50 Heteroarylene, —O—, —C(O), —C(O)NR—, —C(O)O—, —S—, —NR— or —NOR— and R is hydrogen or unsubstituted C 1-50 Alkyl, substituted or unsubstituted C 1-50Aryl, or ethylene glycol repeating units (-(CH 2 CH 2 O) n -, where n is an integer of at least 1 but not more than 20; The biologically active substance conjugate according to claim 13.

16. Y' is a repeating unit of -C(O)-(OCH 2 CH 2 ) u The biologically active substance conjugate of claim 13, which contains -NH-, and u is an integer from 1 to 20.

17. 14. The bioactive agent conjugate of claim 13, wherein Y' comprises glutamic acid, glutamine, glycine, isoleucine or lysine as a moiety.

18. In the (i) bioactive substance conjugate bound to a biotin moiety, a fatty acid moiety, or a combination thereof, The fatty acid portion is [Case 22-1] [Case 22-2] [Case 22-3] [Case 22-4] [Case 22-5] 2. The oral pharmaceutical formulation of claim 1, wherein the oral pharmaceutical formulation is selected from the group comprising:

19. 10. The oral pharmaceutical formulation of claim 1, wherein the excipient comprises a bile acid, a derivative thereof, or a pharma- ceutically acceptable salt thereof.

20. The bile acid is Glycocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, taurocholic acid, deoxycholic acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid and lithocholic acid 20. The oral pharmaceutical formulation of claim 19, wherein the at least one is selected from the group comprising:

21. The bile acid is Chenodeoxycholic acid, deoxycholic acid, cholic acid, glycocholic acid, taurocholic acid and ursodioxycholic acid 20. The oral pharmaceutical formulation of claim 19, which is one selected from the group comprising:

22. The excipient is Alpha-tocopherol, malic acid, fumaric acid, ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, sodium phosphate, calcium phosphate, potassium phosphate, galactose, glucose, maltose, gallic acid, propyl gallate, and pharma- ceutically acceptable salts thereof.

20. The oral pharmaceutical formulation of claim 19, further comprising at least one selected from the group comprising:

23. 20. The oral pharmaceutical formulation of claim 19, wherein the excipient further comprises propyl gallate, or a pharma- ceutically acceptable salt thereof.

24. 2. The oral pharmaceutical formulation of claim 1, wherein the weight ratio of (i) the bioactive agent bound to the biotin moiety, the fatty acid moiety, or a combination thereof to (ii) the excipient is 1:0.01-1000.

25. 2. The oral pharmaceutical formulation of claim 1, wherein the weight ratio of (i) the bioactive agent bound to the biotin moiety, the fatty acid moiety, or a combination thereof to (ii) the excipient is 1:0.1-500.

26. the excipient comprises a bile acid, or a pharma- ceutically acceptable salt thereof, and propyl gallate, or a pharma- ceutically acceptable salt thereof; the weight ratio of the bile acid or a pharma- ceutically acceptable salt thereof to propyl gallate or a pharma-ceutically acceptable salt thereof is 1:0.01-8; 2. The oral pharmaceutical formulation of claim 1.

27. The excipient is bile acid, or a pharma- ceutically acceptable salt thereof, and propyl gallate, or a pharma- ceutically acceptable salt thereof; 1 to 1000 mg of a bile acid or a pharma- ceutically acceptable salt thereof, and 1 to 1000 mg of propyl gallate or a pharma- ceutically acceptable salt thereof Including, 2. The oral pharmaceutical formulation of claim 1.